5-Chlorofuran-2-carboxylic acid → N1-(5-Chlorofuran-2-ylcarbonyl)-N2-[1-(4-pyridyl)piperidin-4-ylmethoxycarbonyl]-1,2-benzenediamine Hydrochloride
반응식
[N:1]1[CH:6]=[CH:5][C:4]([CH:7]([CH:19]2[CH2:24][CH2:23][NH:22][CH2:21][CH2:20]2)[O:8][C:9]([NH:11][C:12]2[C:13]([NH2:18])=[CH:14][CH:15]=[CH:16][CH:17]=2)=[O:10])=[CH:3][CH:2]=1.[Cl:25][C:26]1[O:30][C:29]([C:31](O)=[O:32])=[CH:28][CH:27]=1>>[ClH:25].[Cl:25][C:26]1[O:30][C:29]([C:31]([NH:18][C:13]2[C:12]([NH:11][C:9]([O:8][CH:7]([CH:19]3[CH2:24][CH2:23][NH:22][CH2:21][CH2:20]3)[C:4]3[CH:5]=[CH:6][N:1]=[CH:2][CH:3]=3)=[O:10])=[CH:17][CH:16]=[CH:15][CH:14]=2)=[O:32])=[CH:28][CH:27]=1참가 물질
3
실험 절차
Using the procedure described in Example 168, N1-[1-(4-pyridyl)piperidin-4-ylmethoxycarbonyl]-1,2-benzenediamine (0.61 mmol) and 5-chloro-2-furancarboxylic acid (1.2 mmol), purifying with RPHPLC Method A, yielded 57 mg (22%) of the title compound.
후처리
- custompurifying with RPHPLC Method A